Goldman Sachs Group Inc. Acquires 42,636 Shares of Arcturus Therapeutics Holdings Inc. $ARCT

Key Points

• Goldman Sachs Group Inc. increased its holdings in Arcturus Therapeutics by 9.1%, acquiring an additional 42,636 shares to own approximately 1.88% of the company, valued at $5.4 million.
• Several institutional investors, including ARK Investment Management and Vanguard Group, have also boosted their stakes in Arcturus Therapeutics, which is predominantly owned (94.54%) by institutional investors.
• Arcturus Therapeutics reported a better-than-expected quarterly earnings result with revenue of $28.3 million, surpassing analyst expectations, and a narrower loss per share of ($0.34) compared to a consensus estimate of ($1.11).

Goldman Sachs Group Inc. grew its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 9.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 509,712 shares of the biotechnology company's stock after buying an additional 42,636 shares during the quarter. Goldman Sachs Group Inc. owned approximately 1.88% of Arcturus Therapeutics worth $5,398,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. ARK Investment Management LLC lifted its position in Arcturus Therapeutics by 3.9% during the 1st quarter. ARK Investment Management LLC now owns 2,008,480 shares of the biotechnology company's stock worth $21,270,000 after buying an additional 74,629 shares in the last quarter. Vanguard Group Inc. lifted its position in Arcturus Therapeutics by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 1,748,928 shares of the biotechnology company's stock worth $18,521,000 after buying an additional 64,367 shares in the last quarter. Woodline Partners LP lifted its position in Arcturus Therapeutics by 3.5% during the 4th quarter. Woodline Partners LP now owns 806,912 shares of the biotechnology company's stock worth $13,693,000 after buying an additional 26,956 shares in the last quarter. Millennium Management LLC bought a new stake in Arcturus Therapeutics during the 1st quarter worth about $4,892,000. Finally, Northern Trust Corp lifted its position in Arcturus Therapeutics by 5.6% during the 4th quarter. Northern Trust Corp now owns 256,332 shares of the biotechnology company's stock worth $4,350,000 after buying an additional 13,582 shares in the last quarter. 94.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ARCT shares. Scotiabank reissued an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Citigroup restated a "buy" rating and set a $49.00 price objective (up from $47.00) on shares of Arcturus Therapeutics in a research note on Tuesday, August 12th. HC Wainwright began coverage on shares of Arcturus Therapeutics in a research note on Thursday, September 4th. They set a "buy" rating and a $60.00 price objective on the stock. Leerink Partners lowered their price objective on shares of Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating on the stock in a research note on Friday, August 22nd. Finally, Wells Fargo & Company lowered their price objective on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $50.57.

Arcturus Therapeutics Stock Up 4.7%

Arcturus Therapeutics stock opened at $18.13 on Tuesday. The stock has a market cap of $492.41 million, a P/E ratio of -8.13 and a beta of 2.38. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.04 and a twelve month high of $25.88. The company's 50-day moving average price is $15.47 and its two-hundred day moving average price is $13.39.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.77. The firm had revenue of $28.30 million for the quarter, compared to analysts' expectations of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. Equities analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.